Trial Profile
Pharmacokinetic Study of Extended Infusion Meropenem in Adult Cystic Fibrosis Patient With Exacerbation of Pulmonary Infection.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Feb 2021
Price :
$35
*
At a glance
- Drugs Meropenem (Primary)
- Indications Bacterial infections; Cystic fibrosis-associated respiratory tract infections
- Focus Pharmacokinetics
- 06 Jun 2012 Planned End Date 1 Aug 2012 added as reported by ClinicalTrials.gov.
- 21 Jul 2010 New trial record